Oct. 3 at 12:44 PM
$AKRO $ETNB "On January 27, 2025, Akero Therapeutics, Inc. reported positive clinical trial results from a Phase 2b clinical trial in patients with compensated cirrhosis (fibrosis stage F4) due to MASH, which contributed to heightened industry focus on the FGF21 class of therapeutics and the fibrosis stage F4 segment. Shortly thereafter, representatives of Parent conveyed that Akero Therapeutics, Inc.’s data were a positive indicator for the class and that Parent wished to assemble a cross-functional team to engage in diligence with the intent of exploring a potential collaboration with 89bio."
Are those Parties terminated talks with 89bio are in talks with Akero now? Man, we can't be just a "positive indicator", we are a major player in the MASH field.
$VKTX $RHHBY
https://www.fiercebiotech.com/biotech/after-courting-14-pharmas-89bio-was-left-between-roche-and-hard-place-buyout-talks
